BHVN vs. VTRS, UTHR, RDY, SRPT, CTLT, ROIV, ELAN, LEGN, CERE, and ASND
Should you be buying Biohaven stock or one of its competitors? The main competitors of Biohaven include Viatris (VTRS), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical preparations" industry.
Biohaven (NYSE:BHVN) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, community ranking, media sentiment, earnings, risk and institutional ownership.
Biohaven has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Viatris has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.
In the previous week, Viatris had 2 more articles in the media than Biohaven. MarketBeat recorded 5 mentions for Viatris and 3 mentions for Biohaven. Biohaven's average media sentiment score of 1.41 beat Viatris' score of 0.29 indicating that Biohaven is being referred to more favorably in the media.
Biohaven presently has a consensus target price of $51.63, suggesting a potential upside of 36.07%. Viatris has a consensus target price of $11.00, suggesting a potential upside of 5.87%. Given Biohaven's stronger consensus rating and higher possible upside, equities analysts clearly believe Biohaven is more favorable than Viatris.
Biohaven received 350 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 65.43% of users gave Biohaven an outperform vote while only 35.59% of users gave Viatris an outperform vote.
Biohaven has a net margin of 0.00% compared to Viatris' net margin of -0.37%. Viatris' return on equity of 16.63% beat Biohaven's return on equity.
Viatris has higher revenue and earnings than Biohaven. Viatris is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
88.8% of Biohaven shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 16.0% of Biohaven shares are owned by insiders. Comparatively, 0.3% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Biohaven beats Viatris on 12 of the 18 factors compared between the two stocks.
Get Biohaven News Delivered to You Automatically
Sign up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BHVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biohaven Competitors List
Related Companies and Tools
